The takeaway
Orthopediatrics Corp shows a pronounced seasonal pattern over 9 years of data — strongest in November (+4.5%) and softest in September (−5.1%).
Right now
In July, the stock has fallen 38% of years, averaging −0.3%, roughly 2.4 pts behind the S&P 500.
The full picture
Orthopediatrics Corp's most dependable month has been November, higher in 7 of 9 years; September has been its least reliable, up just 25% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in February (+5.7 pts); it has trailed the market most in September (−5.0 pts).
“vs S&P” is Orthopediatrics Corp’s average for a month minus the S&P 500’s average for that same month — isolating Orthopediatrics Corp’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, November has closed higher 60% of the time versus 78% across the last 9 years — the pattern is weakening.
Figures are the typical (median) November return and how often it rose — the last 5 years versus the last 9(the heatmap’s default window). This verdict stays anchored to that 9-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: November, up in 7 of 9 Novembers while the other eleven tend to blur together.
Its average (+4.5%) and median (+4.5%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even November ranges by 12.4% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: November has cleared the S&P 500 by +2.1 points above the index. That consistency sets it apart from the field, where the average stock manages November only about 62% of the time.
A few other months pull their weight: February, April, and August have also closed higher more often than not. At the other end of the calendar, September has been the soft spot — the weakest of 5 months that average a loss (−5.1%), and the edge isn't year-round — the stock has trailed the S&P 500 in September, March, and October. Its roughest month on record was a −23.0% October in 2023 — a reminder of how hard even a seasonal name can fall.
The pattern has softened of late, November's last five years slipping below its longer-run record.
The takeaway is less about when to buy than what to expect: November aside, the stock's months offer little reliable tilt. With a short 9-year record, the signal is best held loosely.
Short answers on the stock's best month (November), its worst (September), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2017 its best month (November, +4.5%) has run well ahead of its worst (September, −5.1%) — the heatmap above shows how steady that gap has been year to year.
November has been the strongest, averaging +4.5% and closing higher in 7 of 9 years since 2017.
It's the weakest, averaging −5.1% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade